FindMyKOL
Clinical trialNCT03860363CompletedObservational

Experiences With Automated Surgical Drainage in Cardiac Surgery

NCT03860363 is an observational study sponsored by Centese, Inc.. As of 21 Nov 2026, it is completed. It studies Hemorrhage. The registry lists an enrollment of 28 participants at 1 site in 1 country. The registry lists a start date of 22 Feb 2019 and a primary completion date of 30 Mar 2020.

SponsorCentese, Inc.Enrollment28Hemorrhage
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03860363
FieldValue
Registry IDNCT03860363
StatusCompleted
Study typeObservational study
Lead sponsorCentese, Inc.
Enrollment28
Registered sites1
Countries1
ConditionsHemorrhage
Start22 Feb 2019
Primary completion30 Mar 2020
Study completion30 May 2020
Last update posted17 Jul 2020

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the Thoraguard Surgical Drainage System in a real-world clinical environment. It is believed that this system will offer functional and clinical benefits over the current standard of care system for the removal of surgical fluids following cardiac surgery. Observations, experiences, and outcomes in a single hospital setting will be collected for the Thoraguard Surgical Drainage System.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

California, United States1 site
  • Stanford University

    Stanford

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCalifornia: 1 siteCA1NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT03860363

Each answer restates registry values shown on this page.

What is NCT03860363?

NCT03860363 is an observational study sponsored by Centese, Inc.. It studies Hemorrhage.

Who leads NCT03860363?

The registry names Jack Boyd, MD (principal investigator, Stanford University) as the overall official.

Where does NCT03860363 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

When did NCT03860363 end?

The registry lists a primary completion date of 30 Mar 2020 and a study completion date of 30 May 2020. The sponsor last updated the record on 17 Jul 2020.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.